New Delhi, Jan 12 || A team of Australian researchers has developed a new targeted therapeutic approach that could improve treatment for myelofibrosis -- a rare and serious form of blood cancer.
Myelofibrosis disrupts the body’s ability to produce healthy blood cells, leading to fatigue, pain, enlarged spleen, and reduced quality of life.
Although current treatments can help relieve symptoms, there are no treatments to cure the disease.
Rather than just managing symptoms, the research, published in the journal Blood, focused on the abnormal blood cells that drive the disease using immunotherapy.
“People with myelofibrosis are often treated with therapies that help control symptoms, but they don’t selectively target the abnormal cells driving the disease,” said Prof Daniel Thomas, director of the South Australian Health and Medical Research Institute’s (SAHMRI) Blood Cancer programme.